Drug updated on 7/25/2024
Dosage Form | Tablet (oral; 30 mg, 90 mg, 180 mg) |
Drug Class | Kinase inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Brigatinib (Alunbrig) is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
- The information provided is derived from 15 systematic reviews and meta-analyses studies.
- Lorlatinib showed better progression-free survival (PFS), especially in patients with baseline brain metastasis, but had a poorer safety profile compared to Brigatinib.
- Alectinib demonstrated the highest overall survival rates and was safer than Brigatinib, particularly in global and Asian patient populations.
- Ensartinib exhibited superior efficacy over Brigatinib specifically within Asian populations regarding PFS outcomes.
- In second-line treatments post-crizotinib, Alectinib outperformed Brigatinib in terms of PFS while also having a better safety profile; however, both drugs were less safe when compared to other ALK inhibitors like Ceritinib.
- Common adverse events associated with Brigatinib include gastrointestinal reactions, hypertension, coughs, headaches, elevated liver enzymes, and higher incidence rates for Grade 3–4 adverse effects relative to many other such inhibitors.
- Despite its effectiveness in improving quality of life measures among users and intracranial activity in first-line settings, Alunbrig did not surpass alternatives in broader population contexts.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Alunbrig (Brigatinib) Prescribing Information. | 2022 | Takeda Pharmaceutical Company Limited, Cambridge, MA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
BC Cancer protocol summary for first-line treatment of ALK-positive advanced non-small cell lung cancer (NSCLC) with Brigatinib. | 2022 | BC Cancer |
Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group. | 2021 | Journal of the National Cancer Center |
Therapy for stage IV non–small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. | 2021 | Journal of Clinical Oncology |
Metastatic non-small cell lung cancer: ESMO. | 2019 | Annals of Oncology |
Pan-Canadian oncology drug review final clinical guidance report brigatinib (alunbrig) for non-small cell lung cancer. | 2019 | Canadian Agency for Drugs and Technologies in Health |